We envision a world where rapid diagnostics are universally accessible, enabling healthcare providers to make informed decisions swiftly and effectively, transforming patient care globally.
Our Vision
Our vision is to enhance initial prescription and strengthen the practitioner-patient relationship, both in disease detection and routine health monitoring, by equipping frontline healthcare professionals with high-performance rapid diagnostic tests (RDTs).
These RDTs will empower healthcare providers to make immediate, informed decisions based on biomedical data, complementing traditional symptomatic assessments, and can be seamlessly integrated with telemedicine.
Our perspective on the evolution of diagnostic practices aligns with a broader societal trend, where decisions increasingly rely on abundant, real-time quantitative data, meeting a growing demand for immediacy and deeper understanding across all sectors.
Our Mission
Our mission is to develop and commercialize innovative lateral flow immunochromatographic tests, using technologies like single-chain variable fragment antibodies, to enable healthcare professionals – or even patients themselves – to immediately identify pathogens causing observed symptoms.
We are committed to delivering high-performance, user-friendly, and affordable products that address the growing risks of infectious diseases and the need for rapid diagnosis or epidemiological screening, helping to combat or prevent future epidemics and pandemics.
Our Ambition
Our ambition is to be recognized internationally as an innovative company and scientific leader in rapid, patient-near diagnostic tests for detecting infectious diseases and assessing their progression. We aim to become the global leader in this market segment by developing advanced tests based on breakthrough technologies that enable precise, personalized patient care.